Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of PEG-IFN or Roferon-A in responders with CML, malignant melanoma, or renal cell carcinoma
2004-002093-30Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of interferon alfa in chronic myelogenous leukemia (CML), melanoma and renal cell carcinoma (RCC) (3 arms), sponsored by Roche. Started Dec 2005; status: completed.
02
Drugs
interferon alfa
03
Conditions
chronic myelogenous leukemia (CML)melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2004-002093-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002093-30.